High-Response Rates from both Selinexor and Velcade The combination of the two show synergy against Myeloma

Michael Kauffman, MD and CEO from Karyopharm Therapeutics Inc discusses high-response rates from both Selinexor and velcade and the combination of the two show synergy against myeloma at the 2017 Amer... Author: ASHReport Added: 01/22/2018
Source: Oncology Tube - Category: Cancer & Oncology Source Type: podcasts